All In Biotech

Drug Trial Radar · NCT05746559

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 555 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

555

Actual

Start

Apr 6, 2023

Primary completion

Oct 7, 2025

Study completion May 7, 2026

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.

Conditions

  • Chronic Kidney Disease
  • CKD
  • Cardiac Disease
  • Cardiopulmonary Bypass

Interventions

  • PlaceboDrug

    Participants will receive a single weight-based dose of placebo via intravenous infusion.

  • RavulizumabDrug

    Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)

Locations

130 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Orange, California

  • Research Site

    San Francisco, California

  • Research Site

    Stanford, California

  • Research Site

    Chicago, Illinois

  • Research Site

    Boston, Massachusetts

  • Research Site

    Springfield, Massachusetts

  • Research Site

    Kansas City, Missouri

  • Research Site

    Rochester, New York

  • Research Site

    Valhalla, New York

  • Research Site

    Fargo, North Dakota

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Dallas, Texas

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Corrientes, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Brisbane, Australia

  • Research Site

    Monash, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Southport, Australia

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Recife, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Winnipeg, Manitoba, Canada

  • Research Site

    Saint John, New Brunswick, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Kingston, Ontario, Canada

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.